Genmark Diagnostics (GNMK) 11.70 $GNMK Can the
Post# of 273254
Posted On: 09/25/2016 9:11:39 PM
Genmark Diagnostics (GNMK) 11.70 $GNMK
Can the Rally in GenMark Diagnostics (GNMK) Shares Continue?
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 4:46AM CDT
GenMark Diagnostics, Inc (GNMK) has been on the move lately as the stock has risen by 24.8% in the past four weeks, and it is currently trading well above its 20-Day SMA
GNMK: 11.70 (-0.08)
Commit To Purchase GenMark Diagnostics At $7.50, Earn 15.1% Annualized Using Options
StockOptionsChannel.com - Thu Sep 08, 10:51AM CDT
Investors considering a purchase of GenMark Diagnostics, Inc. shares, but tentative about paying the going market price of $8.98/share, might benefit from considering selling puts among the alternative strategies at their disposal.
GNMK: 11.70 (-0.08)
GenMark Diagnostics Reports Q2 Financial Results
BusinessWire - Thu Jul 28, 3:05PM CDT
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the second quarter ended June 30, 2016.
GNMK: 11.70 (-0.08)
GenMark Diagnostics to Present at the 36th Annual Canaccord Genuity Growth Conference
BusinessWire - Wed Jul 27, 4:37PM CDT
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the 36th Annual Canaccord Genuity Growth Conference to be held in Boston, Massachusetts at the InterContinental Hotel on Wednesday, August 10, 2016 at 8:30 a.m. Eastern Time. The presentation will be made available at http://ir.genmarkdx.com.
GNMK: 11.70 (-0.08)
GenMark Achieves CE Mark for its ePlex(R) Sample-to-Answer System
BusinessWire - Wed Jun 08, 3:05PM CDT
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has achieved CE Mark under the European In-Vitro Diagnostic Devices Directive (98/79/EC) for its ePlex Instrument System and ePlex Respiratory Pathogen (RP) Panel.
GNMK: 11.70 (-0.08)
GenMark Diagnostics to Present at the William Blair 36th Annual Growth Stock Conference
BusinessWire - Mon Jun 06, 3:10PM CDT
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the William Blair 36th Annual Growth Stock Conference to be held in Chicago, Illinois at the Four Seasons Hotel on Wednesday, June 15, 2016 at 12:40 p.m. Central Time. The presentation will be made available at http://ir.genmarkdx.com.
GNMK: 11.70 (-0.08)
GenMark Reports First Quarter 2016 Results
BusinessWire - Tue May 03, 3:05PM CDT
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the first quarter ended March 31, 2016.
GNMK: 11.70 (-0.08)
GenMark Diagnostics Schedules First Quarter 2016 Financial Results Conference Call for May 3, 2016
BusinessWire - Tue Apr 19, 1:00PM CDT
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 3, 2016. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 90864115 approximately five minutes prior to the start time.
GNMK: 11.70 (-0.08)
GenMark Announces Preliminary Q4 Financial Results and Initiation of ePlex(TM) Analytical Studies
BusinessWire - Tue Jan 12, 3:05PM CST
--- XT-8 Installed Base Grew by 17 to 633
GNMK: 11.70 (-0.08)
GenMark Diagnostics to Present at the 2016 J.P. Morgan Healthcare Conference
BusinessWire - Wed Dec 30, 12:05PM CST
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 2016 J.P. Morgan Healthcare Conference to be held at the Westin St. Francis Hotel in San Francisco, California on Wednesday, January 13, 2016. The presentation will be delivered by Hany Massarany, President and Chief Executive Officer, and is scheduled to begin at 3:00 pm Pacific Time. The presentation will be made available at http://ir.genmarkdx.com/.
GNMK: 11.70 (-0.08), JPM: 67.25 (-0.14)
Healthcare Sector Equities in Motion -- Tetraphase Pharma, Cardiovascular Systems, Sagent Pharma, and GenMark Diagnostics
ACCESSWIRE - Mon Dec 21, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / December 21, 2015 / Park Lane Advisor has initiated coverage on the following equities: Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH), Cardiovascular Systems Inc. (NASDAQ: CSII), Sagent Pharmaceuticals Inc. (NASDAQ: SGNT), and GenMark Diagnostics Inc. (NASDAQ: GNMK). Free research report on Tetraphase Pharma can be accessed at http://www.parklaneadvisor.com/ On Friday, December 18, 2015, the NASDAQ Composite ended at 4,923.08, down 1.59%, the Dow Jones Industrial Average declined 2.10%, to finish the day at 17,128.55, and the S&P 500 closed at 2,005.55, down 1.78%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
GNMK: 11.70 (-0.08), TTPH: 3.83 (-0.04), CSII: 23.00 (-0.66), SGNT: 21.76 (+0.03)
Can The Uptrend Continue for GenMark (GNMK)?
Zacks Equity Research - Zacks Investment Research - Tue Dec 01, 7:54AM CST
Investors certainly have to be happy with GenMark Diagnostics, Inc. (GNMK) and its short term performance
GNMK: 11.70 (-0.08)
Lisa M.. Giles of GenMark Diagnostics, Inc. (GNMK)-NasdaqGM bought Shares of GNMK
M2 - Thu Nov 05, 8:14AM CST
Lisa M.. Giles, director of GenMark Diagnostics, Inc. (GNMK)-NasdaqGM bought 8,500 shares of GNMK from the open market on 2015-11-04. The stock was up 2.11% after the InsiderCow.com report.
GNMK: 11.70 (-0.08)
GenMark Diagnostics Schedules Third Quarter 2015 Financial Results Conference Call for October 27, 2015
BusinessWire - Thu Oct 15, 1:00PM CDT
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Tuesday, October 27, 2015. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 62237999 approximately five minutes prior to the start time.
GNMK: 11.70 (-0.08)
BUYINS.NET: GNMK SqueezeTrigger Price is $10.35. There is $59,804,136 That Short Sellers Still Need To Cover.
M2 - Fri Sep 18, 12:19PM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Genmark Diagnostics Inc (NASDAQ:GNMK) in real time and just received an alert that GNMK is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 5772600 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $10.35. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
GNMK: 11.70 (-0.08)
The Market for Prenatal, Newborn and Carrier Genetic Testing 2015
M2 - Fri Jul 24, 4:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h7ccfb/the_market_for) has announced the addition of the "The Market for Prenatal, Newborn and Carrier Genetic Testing" report to their offering. The Market for Prenatal, Newborn and Carrier Genetic Testing discusses the technologies and tests used in chromosomal analysis and in the diagnosis of inherited disorders and the detection of carriers of inherited diseases. The growing number of genetic tests has been made possible by advances in technology, including advances in chromosomal analysis - from traditional karyotyping to fluorescence in situ hybridization (FISH), and then to chromosomal microarrays and next generation sequencing. Detection of single gene mutations has been made possible with FISH and polymerase chain reaction (PCR) technology, and is moving into even new possibilities with sequencing based tests that can evaluate large numbers of genes simultaneously. The recent introduction of noninvasive prenatal testing (NIPT) has made it possible to perform prenatal screening of fetuses without the need for invasive procedures. The growing global genetic testing laboratory services market is discussed, including: - Carrier testing - Prenatal testing - Newborn screening - Neonatal/pediatric testing - Testing for adult onset genetic disorders The technologies used for newborn screening discussed in the report include: - Karyotyping - Fluorescence in situ Hybridization - Chromosomal Microarrays - Polymerase Chain Reaction and Other Nucleic Acid Amplification Technologies - DNA Sequencing - Mass Spectrometry - Conventional versus Non-Invasive Prenatal Testing Inherited disease testing was already a large market, but the potential for rapid growth has attracted companies and investors. The report highlights recent activities in this rapidly evolving market. Leading competitors and product developers are listed in the manufacturer profiles. The profiled companies include: Partial List - 23andMe, Inc. - AB SCIEX (A Danaher Corporation Company) - Abbott Laboratories - Affymetrix, Inc. - Agena Bioscience Inc. - Agilent Technologies Inc. - Ambry Genetics Corp. - ARUP Laboratories - Astra Biotech GmbH - Asuragen, Inc. - Athena Diagnostics, Inc. (A Quest Diagnostics Business) - AutoGenomics, Inc. - Berry Genomics Co., Ltd. - BGI-Shenzhen - Bio-Rad Laboratories, Inc. - Bio-Reference Laboratories, Inc. (BRLI) - Centogene AG - Chromsystems Instruments & Chemicals GmbH - Claritas Genomics, Inc. - Color Genomics, Inc. - CombiMatrix Corporation - Counsyl, Inc. - Courtagen Life Sciences, Inc. - GenapSys - Gene by Gene, Ltd. - Genection, Inc. (An Invivoscribe Company) - GeneDx - GenePeeks, Inc. - Genesis Genetics - Genetadi Biotech S.L. - Genetic Technologies Limited / Phenogen Sciences, Inc. (U.S. Division) - GenMark Diagnostics, Inc. - Genoma Group - Genomed AG - GenPath / GenPath Women's Health For more information visit http://www.researchandmarkets.com/research/h7...market_for
GNMK: 11.70 (-0.08), ABT: 42.19 (-0.03), AGMX: (), A: 46.61 (-0.06), CBMX: 2.82 (-0.04), AFFX: 14.01 (+0.02), ATHN: 123.83 (-0.79)
U.S. and Global Molecular Diagnostics in Infectious Disease Testing Market Report (Updated Edition)
M2 - Wed Jul 22, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tj5pr3/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing" report to their offering. This report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics - along with the development of microarray devices to measure analytes in the blood - has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. The purpose of this report is to describe the emerging field of molecular diagnostics in infectious disease testing. The infectious disease space is the most dominant and profitable sector of molecular diagnostics. Topics covered in this study include: - The existing and emerging technologies in the field - The U.S. and global market size for molecular diagnostic products - The profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - Biocartis - BioHelix Corporation (now part of Quidel) - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Great Basin Corporation - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - SACACE - Seegene - Siemens AG - SIRS-Lab - TrimGen - TrovaGene For more information visit http://www.researchandmarkets.com/research/tj5pr3/molecular
GNMK: 11.70 (-0.08), LIFE: 3.30 (-0.03), ABT: 42.19 (-0.03), MYGN: 21.67 (+0.17), AGMX: (), CPHD: 52.50 (unch), ILMN: 179.33 (-0.01), QGEN: 26.66 (-0.21), LMNX: 22.79 (+0.04)
GenMark Diagnostics Schedules Second Quarter 2015 Financial Results Conference Call for August 6, 2015
BusinessWire - Tue Jul 21, 3:05PM CDT
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its second quarter earnings results after market close on Thursday, August 6, 2015. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 87665468 approximately five minutes prior to the start time.
GNMK: 11.70 (-0.08)
Can the Rally in GenMark Diagnostics (GNMK) Shares Continue?
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 4:46AM CDT
GenMark Diagnostics, Inc (GNMK) has been on the move lately as the stock has risen by 24.8% in the past four weeks, and it is currently trading well above its 20-Day SMA
GNMK: 11.70 (-0.08)
Commit To Purchase GenMark Diagnostics At $7.50, Earn 15.1% Annualized Using Options
StockOptionsChannel.com - Thu Sep 08, 10:51AM CDT
Investors considering a purchase of GenMark Diagnostics, Inc. shares, but tentative about paying the going market price of $8.98/share, might benefit from considering selling puts among the alternative strategies at their disposal.
GNMK: 11.70 (-0.08)
GenMark Diagnostics Reports Q2 Financial Results
BusinessWire - Thu Jul 28, 3:05PM CDT
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the second quarter ended June 30, 2016.
GNMK: 11.70 (-0.08)
GenMark Diagnostics to Present at the 36th Annual Canaccord Genuity Growth Conference
BusinessWire - Wed Jul 27, 4:37PM CDT
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the 36th Annual Canaccord Genuity Growth Conference to be held in Boston, Massachusetts at the InterContinental Hotel on Wednesday, August 10, 2016 at 8:30 a.m. Eastern Time. The presentation will be made available at http://ir.genmarkdx.com.
GNMK: 11.70 (-0.08)
GenMark Achieves CE Mark for its ePlex(R) Sample-to-Answer System
BusinessWire - Wed Jun 08, 3:05PM CDT
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has achieved CE Mark under the European In-Vitro Diagnostic Devices Directive (98/79/EC) for its ePlex Instrument System and ePlex Respiratory Pathogen (RP) Panel.
GNMK: 11.70 (-0.08)
GenMark Diagnostics to Present at the William Blair 36th Annual Growth Stock Conference
BusinessWire - Mon Jun 06, 3:10PM CDT
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the William Blair 36th Annual Growth Stock Conference to be held in Chicago, Illinois at the Four Seasons Hotel on Wednesday, June 15, 2016 at 12:40 p.m. Central Time. The presentation will be made available at http://ir.genmarkdx.com.
GNMK: 11.70 (-0.08)
GenMark Reports First Quarter 2016 Results
BusinessWire - Tue May 03, 3:05PM CDT
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the first quarter ended March 31, 2016.
GNMK: 11.70 (-0.08)
GenMark Diagnostics Schedules First Quarter 2016 Financial Results Conference Call for May 3, 2016
BusinessWire - Tue Apr 19, 1:00PM CDT
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 3, 2016. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 90864115 approximately five minutes prior to the start time.
GNMK: 11.70 (-0.08)
GenMark Announces Preliminary Q4 Financial Results and Initiation of ePlex(TM) Analytical Studies
BusinessWire - Tue Jan 12, 3:05PM CST
--- XT-8 Installed Base Grew by 17 to 633
GNMK: 11.70 (-0.08)
GenMark Diagnostics to Present at the 2016 J.P. Morgan Healthcare Conference
BusinessWire - Wed Dec 30, 12:05PM CST
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 2016 J.P. Morgan Healthcare Conference to be held at the Westin St. Francis Hotel in San Francisco, California on Wednesday, January 13, 2016. The presentation will be delivered by Hany Massarany, President and Chief Executive Officer, and is scheduled to begin at 3:00 pm Pacific Time. The presentation will be made available at http://ir.genmarkdx.com/.
GNMK: 11.70 (-0.08), JPM: 67.25 (-0.14)
Healthcare Sector Equities in Motion -- Tetraphase Pharma, Cardiovascular Systems, Sagent Pharma, and GenMark Diagnostics
ACCESSWIRE - Mon Dec 21, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / December 21, 2015 / Park Lane Advisor has initiated coverage on the following equities: Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH), Cardiovascular Systems Inc. (NASDAQ: CSII), Sagent Pharmaceuticals Inc. (NASDAQ: SGNT), and GenMark Diagnostics Inc. (NASDAQ: GNMK). Free research report on Tetraphase Pharma can be accessed at http://www.parklaneadvisor.com/ On Friday, December 18, 2015, the NASDAQ Composite ended at 4,923.08, down 1.59%, the Dow Jones Industrial Average declined 2.10%, to finish the day at 17,128.55, and the S&P 500 closed at 2,005.55, down 1.78%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
GNMK: 11.70 (-0.08), TTPH: 3.83 (-0.04), CSII: 23.00 (-0.66), SGNT: 21.76 (+0.03)
Can The Uptrend Continue for GenMark (GNMK)?
Zacks Equity Research - Zacks Investment Research - Tue Dec 01, 7:54AM CST
Investors certainly have to be happy with GenMark Diagnostics, Inc. (GNMK) and its short term performance
GNMK: 11.70 (-0.08)
Lisa M.. Giles of GenMark Diagnostics, Inc. (GNMK)-NasdaqGM bought Shares of GNMK
M2 - Thu Nov 05, 8:14AM CST
Lisa M.. Giles, director of GenMark Diagnostics, Inc. (GNMK)-NasdaqGM bought 8,500 shares of GNMK from the open market on 2015-11-04. The stock was up 2.11% after the InsiderCow.com report.
GNMK: 11.70 (-0.08)
GenMark Diagnostics Schedules Third Quarter 2015 Financial Results Conference Call for October 27, 2015
BusinessWire - Thu Oct 15, 1:00PM CDT
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Tuesday, October 27, 2015. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 62237999 approximately five minutes prior to the start time.
GNMK: 11.70 (-0.08)
BUYINS.NET: GNMK SqueezeTrigger Price is $10.35. There is $59,804,136 That Short Sellers Still Need To Cover.
M2 - Fri Sep 18, 12:19PM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Genmark Diagnostics Inc (NASDAQ:GNMK) in real time and just received an alert that GNMK is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 5772600 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $10.35. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
GNMK: 11.70 (-0.08)
The Market for Prenatal, Newborn and Carrier Genetic Testing 2015
M2 - Fri Jul 24, 4:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h7ccfb/the_market_for) has announced the addition of the "The Market for Prenatal, Newborn and Carrier Genetic Testing" report to their offering. The Market for Prenatal, Newborn and Carrier Genetic Testing discusses the technologies and tests used in chromosomal analysis and in the diagnosis of inherited disorders and the detection of carriers of inherited diseases. The growing number of genetic tests has been made possible by advances in technology, including advances in chromosomal analysis - from traditional karyotyping to fluorescence in situ hybridization (FISH), and then to chromosomal microarrays and next generation sequencing. Detection of single gene mutations has been made possible with FISH and polymerase chain reaction (PCR) technology, and is moving into even new possibilities with sequencing based tests that can evaluate large numbers of genes simultaneously. The recent introduction of noninvasive prenatal testing (NIPT) has made it possible to perform prenatal screening of fetuses without the need for invasive procedures. The growing global genetic testing laboratory services market is discussed, including: - Carrier testing - Prenatal testing - Newborn screening - Neonatal/pediatric testing - Testing for adult onset genetic disorders The technologies used for newborn screening discussed in the report include: - Karyotyping - Fluorescence in situ Hybridization - Chromosomal Microarrays - Polymerase Chain Reaction and Other Nucleic Acid Amplification Technologies - DNA Sequencing - Mass Spectrometry - Conventional versus Non-Invasive Prenatal Testing Inherited disease testing was already a large market, but the potential for rapid growth has attracted companies and investors. The report highlights recent activities in this rapidly evolving market. Leading competitors and product developers are listed in the manufacturer profiles. The profiled companies include: Partial List - 23andMe, Inc. - AB SCIEX (A Danaher Corporation Company) - Abbott Laboratories - Affymetrix, Inc. - Agena Bioscience Inc. - Agilent Technologies Inc. - Ambry Genetics Corp. - ARUP Laboratories - Astra Biotech GmbH - Asuragen, Inc. - Athena Diagnostics, Inc. (A Quest Diagnostics Business) - AutoGenomics, Inc. - Berry Genomics Co., Ltd. - BGI-Shenzhen - Bio-Rad Laboratories, Inc. - Bio-Reference Laboratories, Inc. (BRLI) - Centogene AG - Chromsystems Instruments & Chemicals GmbH - Claritas Genomics, Inc. - Color Genomics, Inc. - CombiMatrix Corporation - Counsyl, Inc. - Courtagen Life Sciences, Inc. - GenapSys - Gene by Gene, Ltd. - Genection, Inc. (An Invivoscribe Company) - GeneDx - GenePeeks, Inc. - Genesis Genetics - Genetadi Biotech S.L. - Genetic Technologies Limited / Phenogen Sciences, Inc. (U.S. Division) - GenMark Diagnostics, Inc. - Genoma Group - Genomed AG - GenPath / GenPath Women's Health For more information visit http://www.researchandmarkets.com/research/h7...market_for
GNMK: 11.70 (-0.08), ABT: 42.19 (-0.03), AGMX: (), A: 46.61 (-0.06), CBMX: 2.82 (-0.04), AFFX: 14.01 (+0.02), ATHN: 123.83 (-0.79)
U.S. and Global Molecular Diagnostics in Infectious Disease Testing Market Report (Updated Edition)
M2 - Wed Jul 22, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tj5pr3/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing" report to their offering. This report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics - along with the development of microarray devices to measure analytes in the blood - has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. The purpose of this report is to describe the emerging field of molecular diagnostics in infectious disease testing. The infectious disease space is the most dominant and profitable sector of molecular diagnostics. Topics covered in this study include: - The existing and emerging technologies in the field - The U.S. and global market size for molecular diagnostic products - The profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - Biocartis - BioHelix Corporation (now part of Quidel) - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Great Basin Corporation - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - SACACE - Seegene - Siemens AG - SIRS-Lab - TrimGen - TrovaGene For more information visit http://www.researchandmarkets.com/research/tj5pr3/molecular
GNMK: 11.70 (-0.08), LIFE: 3.30 (-0.03), ABT: 42.19 (-0.03), MYGN: 21.67 (+0.17), AGMX: (), CPHD: 52.50 (unch), ILMN: 179.33 (-0.01), QGEN: 26.66 (-0.21), LMNX: 22.79 (+0.04)
GenMark Diagnostics Schedules Second Quarter 2015 Financial Results Conference Call for August 6, 2015
BusinessWire - Tue Jul 21, 3:05PM CDT
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its second quarter earnings results after market close on Thursday, August 6, 2015. Management will hold a conference call to review the Company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 87665468 approximately five minutes prior to the start time.
GNMK: 11.70 (-0.08)
(0)
(0)Scroll down for more posts ▼